Brain Tumor Res Treat.  2025 Jan;13(1):17-22. 10.14791/btrt.2024.0041.

Second Primary Tumors After Primary Brain Tumors and Vice Versa: A Single-Center, Retrospective Study

• Angez M
• Tariq R
• Zafar A
• Ahmed AA
• Hameed AN
• Waqar U
• Enam SA

• KMID: 2565045
• DOI: http://doi.org/10.14791/btrt.2024.0041

Abstract

Background
Advancements in surgery, chemotherapy, and radiotherapy have improved survival for brain tumor patients, increasing the risk of second primary tumors (SPTs) among long-term survivors. This study examines the types and risks of SPTs in brain tumor patients presenting at a tertiary care hospital.
Methods
This single-center, retrospective study explored occurrences of SPTs following prima- ry brain tumors and occurrences of brain tumors as SPTs following primary extra neural tumors. A total of 41 patients were included and analyzed presenting with histologically confirmed SPTs between 1st January 2000 and 31st December 2020.
Results
The study included 41 patients with SPTs, primarily female (65.9%). Of these, 20 pa- tients (48.7%) developed SPTs after a primary brain tumor, while 21 patients (51.2%) developed brain tumors as SPTs after extra-neural tumors. Among patients who developed SPTs after brain tumors (n=20), meningioma (n=8, 40.0%) and pituitary adenoma (n=6, 30.0%) were the most prevalent first primary tumors (FPTs) while breast tumors predominated as SPTs (n=4, 20.0%). Survival analysis indicated younger mean age (44.5 years) for patients marked alive, compared to those marked deceased (57.0 years) and those with unknown outcomes (63.0 years).
Conclusion
Based on this retrospective analysis, the median age at diagnosis was 44.5 years, with a considerable number of patients (36.6%) having uncertain outcomes at follow-up due to incomplete records. These findings highlight the need for improved follow-up data management to better assess long-term survival in patients with SPTs following brain tumors.

Reference

1. DeAngelis LM. Brain tumors. N Engl J Med. 2001; 344:114–123. PMID: 11150363.

2. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74:229–263. PMID: 38572751.

3. Lapointe S, Perry A, Butowski NA. Primary brain tumours in adults. Lancet. 2018; 392:432–446. PMID: 30060998.

4. Silva-Vieira M, Carrilho Vaz S, Esteves S, Ferreira TC, Limbert E, Salgado L, et al. Second primary cancer in patients with differentiated thyroid cancer: does radioiodine play a role? Thyroid. 2017; 27:1068–1076. PMID: 28614983.

5. Kim JY, Jackman JG, Woodring S, McSherry F, Herndon JE, Desjardins A, et al. Second primary cancers in long-term survivors of glioblastoma. Neurooncol Pract. 2019; 6:386–391. PMID: 31555453.

6. Rapiti E, Fioretta G, Verkooijen HM, Zanetti R, Schmidlin F, Shubert H, et al. Increased risk of colon cancer after external radiation therapy for prostate cancer. Int J Cancer. 2008; 123:1141–1145. PMID: 18546265.

7. Zheng X, Li X, Wang M, Shen J, Sisti G, He Z, et al. Second primary malignancies among cancer patients. Ann Transl Med. 2020; 8:638. PMID: 32566575.

8. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003; 89:1638–1644. PMID: 14583762.

9. Yang J, Terebelo HR, Zonder JA. Secondary primary malignancies in multiple myeloma: an old NEMESIS revisited. Adv Hematol. 2012; 2012:801495. PMID: 22851973.

10. Li Z, Wang K, Shi Y, Zhang X, Wen J. Incidence of second primary malignancy after breast cancer and related risk factors—is breast-conserving surgery safe? A nested case-control study. Int J Cancer. 2020; 146:352–362. PMID: 30861567.

11. Kutsenko A, Berrington de Gonzalez A, Curtis RE, Rajaraman P. Risk of second benign brain tumors among cancer survivors in the surveillance, epidemiology, and end results program. Cancer Causes Control. 2014; 25:659–668. PMID: 24682745.

12. Schoenberg BS, Christine BW, Whisnant JP. Nervous system neoplasms and primary malignancies of other sites. The unique association between meningiomas and breast cancer. Neurology. 1975; 25:705–712. PMID: 1171403.

13. Wang W. Increased incidence of second primary malignancy in patients with malignant astrocytoma: a population-based study. Biosci Rep. 2019; 39:BSR20181968. PMID: 31138756.

14. Sakthivel V, Ganesh KM, McKenzie C, Boopathy R, Selvaraj J. Second malignant neoplasm risk after craniospinal irradiation in X-ray-based techniques compared to proton therapy. Australas Phys Eng Sci Med. 2019; 42:201–209. PMID: 30725439.

15. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013; 155:462–477. PMID: 24120142.

16. Berberich A, Hielscher T, Kickingereder P, Winkler F, Drüschler K, Riedemann L, et al. Nonmeasurable speckled contrast-enhancing lesions appearing during course of disease are associated with IDH mutation in high-grade astrocytoma patients. Int J Radiat Oncol Biol Phys. 2018; 102:1472–1480. PMID: 30071292.

17. Boston RC, Sumner AE. STATA: a statistical analysis system for examining biomedical data. Adv Exp Med Biol. 2003; 537:353–369. PMID: 14995047.

18. Awan UA, Guo X, Khattak AA, Hassan U, Khan S. Economic crises and cancer care in Pakistan-timely action saves lives. Lancet. 2024; 403:613–614. PMID: 38368005.

19. Brada M, Ford D, Ashley S, Bliss JM, Crowley S, Mason M, et al. Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. BMJ. 1992; 304:1343–1346. PMID: 1611331.

20. Chojnacka M, Pędziwiatr K, Skowrońska-Gardas A, Perek-Polnik M, Perek D, Olasek P. Second brain tumors following central nervous system radiotherapy in childhood. Br J Radiol. 2014; 87:20140211. PMID: 24968876.

21. Ho VK, Reijneveld JC, Enting RH, Bienfait HP, Robe P, Baumert BG, et al. Changing incidence and improved survival of gliomas. Eur J Cancer. 2014; 50:2309–2318. PMID: 24972545.

22. Hemminki K, Försti A, Ji J. Incidence and familial risks in pituitary adenoma and associated tumors. Endocr Relat Cancer. 2007; 14:103–109. PMID: 17395979.

23. Miller RE. Breast cancer and meningioma. J Surg Oncol. 1986; 31:182–183. PMID: 3724170.

24. Zheng Y, Sun Y, Kuai Y, Fu G, An H, Chen J, et al. Gene expression profiling for the diagnosis of multiple primary malignant tumors. Cancer Cell Int. 2021; 21:47. PMID: 33514366.

25. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013; 19:764–772. PMID: 23209033.

26. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008; 116:597–602. PMID: 18985363.

27. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009; 174:1149–1153. PMID: 19246647.

28. Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012; 17:72–79. PMID: 22180306.

29. Duffner PK, Kun LE, Burger PC, Horowitz ME, Cohen ME, Sanford RA, et al. Postoperative chemotherapy and delayed radiation in infants and very young children with choroid plexus carcinomas. Pediatr Neurosurg. 1995; 22:189–196. PMID: 7619719.